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Abstract
Objective—Recent evidence suggests that antibiotic use, which alters the gut microbiome, is
associated with an increased risk of colorectal cancer. However, the association between antibiotic
use and risk of colorectal adenoma, the precursor for the majority of colorectal cancers, has not
been investigated.

Author Manuscript

Design—We prospectively evaluated the association between antibiotic use at age 20–39 and 40–
59 (assessed in 2004) and recent antibiotic use (assessed in 2008) with risk of subsequent
colorectal adenoma among 16,642 women aged ≥60 enrolled in the Nurses’ Health Study who
underwent at least one colonoscopy through 2010. We used multivariate logistic regression to
calculate odds ratios (ORs) and 95% confidence intervals (CIs).
Results—We documented 1,195 cases of adenoma. Increasing duration of antibiotic use at age
20–39 (Ptrend=0.002) and 40–59 (Ptrend=0.001) was significantly associated with an increased risk
of colorectal adenoma. Compared to non-users, women who used antibiotics for ≥2 months
between age 20–39 had a multivariable OR of 1.36 (95% CI: 1.03–1.79). Women who used ≥2
months of antibiotics between age 40–59 had a multivariable OR of 1.69 (95% CI: 1.24–2.31).
The associations were similar for low-risk vs. high-risk adenomas (size ≥1 cm, or with
tubulovillous/villous histology, or ≥3 detected lesions), but appeared modestly stronger for
proximal compared with distal adenomas. In contrast, recent antibiotic use within the past 4 years
was not associated with risk of adenoma (Ptrend=0.44).

Author Manuscript

Conclusions—Long-term antibiotic use in early to middle adulthood was associated with
increased risk of colorectal adenoma.
Keywords
antibiotics; colorectal adenomas; colonic microflora

INTRODUCTION

Author Manuscript

In recent years, antibiotic use has increased dramatically in the U.S.1 Accumulating
evidence suggests that exposure to antibiotics may be associated with risk for chronic
illnesses such as inflammatory bowel disease,23 celiac disease,4 and obesity.56 It is
hypothesized that the link between antibiotics and disease pathogenesis may be mediated by
their effect on the taxonomic, genomic, and functional capacity of the gut microbiota.7–9
Similarly, increasing data have supported a role for the gut microbiota in colorectal
carcinogenesis.10–12 Thus, antibiotics and their effects on the gut microbiome may lead to
the promotion of biological pathways that initiate or promote colorectal neoplasia.13–15
Limited studies from cancer registries and healthcare claims in Europe with short-term
follow-up suggest an association between antibiotic exposure and colorectal cancer.16–18
Although these data are intriguing, limitations of these studies influence their interpretation.
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First, the associations of antibiotics with colorectal cancer, particularly with shorter term
follow-up may be due to residual confounding or reverse causality. For example, antibiotics
may be more likely to be prescribed for symptoms associated with colorectal cancer or
conditions that predispose to cancer prior to a formal diagnosis. Second, the association of
recent antibiotic exposure with a higher likelihood of colorectal cancer diagnosis may also
be indicative of closer or more frequent medical surveillance among these antibiotic users.
Third, prior studies were based on cohorts that had limited information on potential lifestyle
factors influencing the risk of colorectal cancer or the use of antibiotics. Fourth, given that
colorectal cancer is believed to typically develop over at least a decade, the short-term
follow-up data compiled by these studies are unlikely to capture the role of antibiotics in the
initiation of colorectal neoplasia. Finally, these studies are derived from prescription records,
which may not reflect actual use of these agents.

Author Manuscript

To address these limitations, we examined the association of both past and recent antibiotic
use with risk of colorectal adenoma, the precursor of the majority of colorectal cancers,
among women enrolled in the Nurses’ Health Study (NHS), which has collected detailed
information on antibiotic use and lifestyle risk factors for colorectal cancer and endoscopic
screening practices since 2004 and prospectively documented cases of adenoma through
2010. Because colorectal adenomas are largely asymptomatic and detected only during a
colonoscopy, an association between antibiotic use and adenoma among a cohort of
individuals uniformly undergoing colonoscopy would be less likely to be confounded by
symptoms associated with colorectal cancer or differential exposure to medical care.

METHODS
Study population

Author Manuscript

The NHS is an ongoing prospective cohort study of 121,700 U.S. female nurses aged 30–55
at enrollment in 1976. Participants have been mailed questionnaires every 2 years since
baseline to collect data on demographics, lifestyle factors, medical history, and disease
outcomes, and every 4 years to collect dietary data. In this analysis, we excluded participants
with a diagnosis of cancer (except non-melanoma skin cancer), ulcerative colitis, or
colorectal polyp before 2004. To reduce the potential for detection bias, we restricted the
analysis to 16,642 women aged 60 and above in 2004 who reported their history of antibiotic
use through age 59 via the 2004 questionnaire and subsequently reported having undergone
at least one colonoscopy between 2004 and 2010 on biennial follow-up questionnaires. This
study was approved by the institutional review board at the Brigham and Women’s Hospital.
Ascertainment of colorectal adenoma cases and controls

Author Manuscript

On each biennial questionnaire, we asked whether participants had undergone a
colonoscopy; what the indications for these procedures were; whether colon or rectal polyps
had been diagnosed in the past two years; and if they had, the date of diagnosis. When a
diagnosis was reported, we obtained informed consent to acquire medical records and
pathology reports. Investigators blinded to any exposure information reviewed all records
and extracted data on histological type, anatomic location, size and number of the polyps. If
more than one adenoma was diagnosed, the subject was classified according to the largest
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and most advanced histologic adenoma. Adenomas in the cecum, ascending colon, hepatic
flexure, transverse colon or splenic flexure were classified as proximal; adenomas in the
descending or sigmoid colon were classified as distal; and adenomas in the rectum or
rectosigmoid junction were classified as rectal. We also grouped adenoma cases according to
their features and subsequent likelihood of developing future advanced neoplasia: high-risk,
defined as at least one adenoma ≥1 cm in diameter, or with advanced histology
(tubulovillous/villous histologic features or high-grade or severe dysplasia), or ≥3 adenomas
regardless of histology or size vs. low-risk, which included all other adenomas,19 size (large:
≥1cm vs. small: <1 cm), histology (tubulovillous/villous vs. tubular), and multiplicity (≥3 vs.
<3). Cases and controls were separately defined in each two-year period: all newly
diagnosed adenomas were considered as cases and all the participants who reported
colonoscopy but without a diagnosis of adenoma were defined as controls.

Author Manuscript

Assessment of antibiotic use
In 2004, participants reported their total time using antibiotics (excluding skin creams,
mouthwash or Isoniazid) for the time periods between age 20–39 and 40–59. The responses
were recorded in 8 categories (ranging from none to 5+ years). In 2008, participants recalled
their total amount of time of antibiotic use (excluding skin creams, mouthwash or Isoniazid)
during the past 4 years in 7 categories (ranging from none to 3+ years). They also reported
the most common reason that an antibiotic was used, including respiratory infection, urinary
tract infection (UTI), acne/rosacea, chronic bronchitis, dental, and other reason.
Statistical analysis

Author Manuscript

We evaluated the association between antibiotic use at age 20–39 and 40–59 (assessed in
2004) with risk of colorectal adenoma among women who reported a colonoscopy between
2004 and 2010 as the main analyses. The minimum detectable OR was 1.45 when
comparing individuals who used antibiotics for 2 mo+ at age 20–39 to non-users, and 1.52
for individuals who used antibiotics for 2 mo+ compared to non-users at age 40–59. We also
examined exposure to antibiotics over the preceding 4 years (assessed in 2008) and risk of
colorectal adenoma among women who had a colonoscopy between 2008–2010. In
secondary analyses, we investigated the association between antibiotic exposure during each
time period and risk of high vs. low-risk adenoma, as well as according to anatomic location,
size, histological type, and number of adenomas. As an exploratory analysis, we examined
the association between the most common reason for antibiotic use (assessed in 2008) and
risk of colorectal adenoma among women who had a colonoscopy between 2008–2010.

Author Manuscript

To account for the possibility that a single individual may have undergone multiple
endoscopies between 2004 and 2010 and to handle time-varying exposure and covariates
efficiently, we used an Andersen-Gill data structure with a new record for each 2-year
follow-up period during which a participant underwent a colonoscopy. Exposure and
covariates were set to their values at the time that the questionnaire was returned. Once a
participant was diagnosed with adenoma, she was censored in all later follow-up cycles. Age
and multivariable-adjusted logistic regressions for clustered data (PROC GENMOD) were
used to account for repeated observations (i.e. multiple endoscopies) and to calculate odds
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ratios (ORs) approximating relative risks. Tests for trend were conducted using the median
of the duration of antibiotic therapy as a continuous variable.

Author Manuscript

In age-adjusted models, we controlled for age in 5-year intervals, time period of
colonoscopy (in 2-year intervals); number of endoscopies (continuous); time in years since
the most recent endoscopy (continuous); and reason for the current colonoscopy(screening/
symptoms/missing). In the multivariable models, we additionally adjusted for the following
potential confounders (cumulatively updated when applicable): history of colorectal cancer
in a first degree relative (yes/no); personal history of diabetes (yes/no); use of menopausal
hormone therapy (MHT) (never/past/current); body mass index (kg/m2 in quintiles); height
(continuous); regular aspirin use (yes/no); current use of multivitamin (yes/no); physical
activity (metabolic equivalent task [MET]-hrs/wk in quintiles); smoking (pack-years in
categories: never smoker, 1–4.9, 5–19.9, 20–39.9, 40+); alcohol intake (g/d in categories:
<5, 5–9.9, 10–14.9, 15–29.9, 30+); total calories (kcal/d in quintiles); folate intake (μg/d in
quintiles); calcium intake (mg/d in quintiles); red and processed meat intake (servings/d in
quintiles). To control for potential confounding by multiple dietary factors, we adjusted for
Alternate Healthy Eating Index (AHEI)-2010 (in quintiles),20 which features greater
consumption of vegetables (excluding potatoes), fruits (excluding juices); whole grains;
nuts, legumes and vegetable protein, long chain omega-3 fatty acids, polyunsaturated fatty
acids; and a lower consumption of sugar-sweetened beverages, red/processed meat, sodium,
trans fat, and moderate alcohol consumption. Adherence to the AHEI-2010 has been
associated with reduced risk of cardiovascular disease, diabetes and cancer in our cohorts.21
Because alcohol was included as a separate term in our model, we used a modified
AHEI-2010 without alcohol consumption. All the analyses were performed using SAS v 9.4
(SAS Institute, Cary, NC). All the statistical tests were two-sided and P values less than 0.05
were considered statistically significant.

Author Manuscript

RESULTS
We documented 1,195 newly diagnosed adenomas among 16,642 women aged ≥60 who had
at least one colonoscopy between 2004 and 2010 and reported information on antibiotic use.
We calculated the distribution of potential risk factors for adenomas according to duration of
antibiotic use during age 20–39 (Table 1). Women who used antibiotics for longer duration
were generally similar to women who did not have any antibiotic treatment in terms of
family history of colorectal cancer, personal disease/screening history and lifestyle factors,
but were more likely to regularly use menopausal hormone therapy and aspirin and undergo
colonoscopy for symptoms (e.g. abdominal pain, diarrhea, constipation) rather than routine
screening.

Author Manuscript

An increasing total exposure to antibiotics at age 20–39 was significantly associated with a
higher risk of colorectal adenoma. Compared to non-users, women who used antibiotics for
≥2 months during age 20–39 had a multivariable OR for adenoma of 1.36 (95% CI, 1.03–
1.79) (Ptrend=0.002) (Table 2). The associations were similar for high-risk (size ≥1cm, or
with tubulovillous/villous histology, or ≥3) compared with low-risk adenomas (Table 2 and
Supplemental Table 1). In contrast, a somewhat stronger association was observed for
adenomas located in the proximal compared to distal colon (Table 2).
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Similarly, antibiotic use during age 40–59 was associated with an increased risk of colorectal
adenoma. Women who used ≥2 months of antibiotics during age 40–59 had a multivariable
OR for adenoma of 1.69 (95% CI, 1.24–2.31) (Table 3 and Supplemental Table 2). The
associations were similar for low-risk vs. high-risk adenomas (Table 3). Longer duration of
antibiotic treatment appeared to be more strongly associated with proximal adenomas (Table
3). Compared to non-users of antibiotics between age 20–39 and 40–59, women who used
antibiotics for more than 15 days between both age 20–39 and more than 15 days between
age 40–59 had a multivariable OR for adenoma of 1.73 (95% CI,1.19–2.51) (Supplemental
Table 3).
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In contrast, recent antibiotic use did not appear associated with risk of colorectal adenoma.
Among women who had a colonoscopy between 2008 and 2010, antibiotic use in the past 4
years was not associated with risk of adenoma (Ptrend=0.44) (Table 4). In addition, none of
the indications for antibiotic use appeared to be significantly associated with risk of
adenoma (Supplemental Table 4).

DISCUSSION
In this prospective analysis nested in a large cohort of women with well-characterized risk
factors for colorectal neoplasia, exposure to antibiotics earlier in life (age 20–39 and 40–59)
was significantly associated with an increased risk for colorectal adenoma after age 60. In
contrast, more recent antibiotic use (within 4 years) was not associated with risk. To the best
of our knowledge, this study is the first to link duration of antibiotic use, in a dosedependent fashion, to colorectal adenoma, the primary precursor of colorectal cancer.

Author Manuscript
Author Manuscript

Our results are supported by prior studies of antibiotics and risk of colorectal cancer. A
cohort study in Finland found that compared to people with ≤1 prescription for antibiotics,
people who had ≥6 prescriptions had a 15% increased risk of developing colon cancer
during up to 9 years of follow-up.16 With a median follow-up of 6.2 years, a nested casecontrol study in The Health Improvement Network (THIN) of the UK suggested that the first
antibiotic exposure to penicillins, cephalosporins, TMP-SMX (Trimethoprim/
sulfamethoxazole), and nitroimidazoles was associated with an increased risk of colorectal
cancer within 1–5 years. Although no association was noted for exposure to most antibiotics
>5 years before diagnosis, initial use of penicillin >10 years prior to diagnosis was
associated with an increased risk of colorectal cancer, suggesting a possible role in the
earliest stage of initiation of colorectal neoplasia.17 A nested case-control study from the
Netherlands also observed an increased risk of colorectal cancer associated with antibiotic
use within 1–6 years before diagnosis.18 Finally, in a nested case-control study among
diabetic patients in Taiwan, prescriptions for antibiotics with anaerobic coverage, but not
anti-aerobic coverage, were linked to an elevated risk of colorectal cancer.22 Our study
significantly extends the findings of these prior studies by demonstrating an association of
antibiotics with colorectal adenoma and its location, providing additional support that the
association of antibiotics with colorectal cancer may be causal.
The proposed link between exposure to antibiotics and development of colorectal neoplasia
is biologically plausible. Antibiotics shift the gut microbiota to temporally quasi-stable or
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alternative stable states.2324 Although it is unknown what factors influence either the
recovery of gut microbiota to its native state or the development of alternative states after
antibiotic exposure,25 this dysbiosis is generally marked by a loss of diversity, alternations in
the abundance of specific taxa, shifts in metabolic capacity, and reduced resistance to
colonization by invading pathogens.1426–28 Studies have observed depletion of the phyla
Bacteroidetes, Firmicutes (Clostridia), and Proteobacteria (Enterobacteriaceae), but
enrichment in Fusobacteria in patients with colorectal cancer.2930 The interactions of these
dysbiotic microbiota with mucosal immune and epithelial cells may be critical in the
initiation and/or promotion of colorectal carcinogenesis.10121431 The higher bacterial
concentration and fermentation in the proximal colon32 may also explain the observed
stronger link between antibiotics and proximal adenomas. Finally, it is worth noting that
pathogens that necessitate the use of antibiotics may induce inflammation, a known risk for
colorectal cancer.33 Thus, it is possible that the observed link between antibiotics and
adenoma may be mediated by inflammation.

Author Manuscript

Strengths of our study include detailed assessment of antibiotic use in early and middle
adulthood, as well as recent antibiotic exposure and prospective follow-up to examine the
influence of long-term and short-term impact of antibiotics on colorectal carcinogenesis with
minimal recall bias. We were also able to control for a range of important potential
confounders, (e.g. dietary factors and physical activity), which were not included in previous
analyses. In addition, although we have limited power to evaluate the association with
adenomas defined by their anatomic location, it is worth noting that earlier life antibiotic
exposure was more strongly associated with proximal adenomas, the subtype of adenoma
that is less likely to be detected by screening colonoscopy.34 Finally, our data, collected from
health professionals, are more likely to reflect actual use of these agents in contrast to prior
studies that relied on prescription information.

Author Manuscript

Our study also had several limitations. First, we did not access information on spectrum and
route of administration of antibiotics. As a result, we are not able to investigate the
differential effects of distinct antimicrobial classes. Nonetheless, if the effect of antibiotics
on cancer is specific to only specific subtypes of antibiotics, our findings would be expected
to be diluted. Moreover, it has been hypothesized that the influence of antibiotics on
carcinogenesis is not dependent on the antimicrobial spectrum of the agent since the gut
microbial ecosystem is co-dependent; thus perturbations specific to certain strains would be
expected to have a broader impact on overall gut microbial composition and function.1428
Nonetheless, the long-term impact of recently more commonly used antibiotics (e.g.
rifaximin) should be examined in future studies. Second, measurement errors associated
with recall of exposure to antibiotics during early life periods may be present. However, they
would be expected to be non-differential to adenoma diagnosis. Third, as an observational
study, the potential for residual confounding cannot be ruled out. Fourth, because age of
exposure is closely correlated with duration of exposure and time since last exposure, we
were unable to disentangle these factors to examine the independent association of these
variables on risk. The specific timing of antibiotic exposure relative to development of
adenoma is unclear since the diagnosis of adenoma was dependent on undergoing
colonoscopy. Thus, some adenomas may have been prevalent at the time of antibiotic
exposure but not yet detected. However, we observed an association of antibiotic use several
Gut. Author manuscript; available in PMC 2019 April 01.
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decades before colonoscopy, minimizing this likelihood. Finally, the generalizability of our
data to other populations, particularly men and other racial or ethnic groups, is not known.
Thus, further research is needed to confirm these findings.
In conclusion, early to middle adulthood antibiotic use was associated with increased risk of
colorectal adenoma, especially in the proximal colon. These data provide additional support
for the association of antibiotics with colorectal cancer and the potential mediating role of
the gut microbiome in carcinogenesis. Additional studies investigating the impact of
antibiotic exposure with gut microbial composition and function, particularly in relation to
the mechanisms underlying colorectal carcinogenesis, are warranted.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Summary Box
1. What is already known about this subject: 3–4 bullet points
•

Increasing data have supported a role for the gut microbiota in colorectal
carcinogenesis.

•

Limited studies from cancer registries and healthcare claims with short-term
follow-up suggest an association between antibiotic exposure and colorectal
cancer.

•

The association between antibiotic use and risk of colorectal adenoma, the
precursor for the majority of colorectal cancers, has not been investigated.

2. What are the new findings: 3–4 bullet points

Author Manuscript

•

Exposure to antibiotics earlier in life (age 20–39 and 40–59) was significantly
associated with an increased risk for colorectal adenoma after age 60.

•

More recent antibiotic use (within 4 years) was not associated with risk of
colorectal adenoma.

•

These data provide additional support for the association of antibiotics with
colorectal cancer and the potential mediating role of the gut microbiome in
carcinogenesis.

3. How might it impact on clinical practice in the foreseeable future?
•

Author Manuscript

The findings, if confirmed by other studies, suggest the potential need to limit
the use of antibiotics and sources of inflammation that may drive tumor
formation.

Author Manuscript
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492(160)
1103(337)
5.4(2.5)
48.8(8.6)

Folate intake, μg/d

Calcium intake, mg/d

Red meat intake, servings/wk

Alternate Healthy Eating Index (AHEI) 2010†

2.4(1.0)

18.8(18.7)

Pack-years among ever smokers

1674(380)

19.9(16.3)

Physical activity, MET-hrs/wk

Total calorie intake, kcal/d

74

Current use of multivitamin, %

Alcohol intake, g/d

39

Regular use of aspirin, %

2.8(1.7)

Current endoscopy due to symptoms, %

Number of previous endoscopies

16

Current hormone therapy use, %

48.6(8.6)

5.6(2.7)

1095(345)

499(170)

1708(400)

2.3(0.9)

21.1(19.3)

18.9(16.4)

77

42

3.0(1.8)

19

19

25.6(4.4)

164(6)

8.7

19

68.9(5.8)

<15 d

47.8(8.9)

5.9(2.7)

1110(327)

500(166)

1774(404)

2.3(0.9)

19.0(17.5)

18.0(15.8)

79

45

3.0(1.8)

21

21

25.7(4.4)

164(6)

9.5

18

68.0(5.5)

15 d-2 mo

48.8(9.3)

5.8(2.7)

1159(358)

530(175)

1809(410)

2.3(0.9)

18.5(17.7)

19.4(16.8)

79

47

3.1(1.8)

25

25

25.4(4.4)

164(6)

8.8

20

67.2(5.1)

2 mo+

Without alcohol intake.

†

All values other than age have been directly standardized to age distribution (in 5-year age group) of all the participants. Mean (SD) was presented for continuous variables.

*

kg/m2

BMI,

164(6)
25.4(4.2)

Height, cm

21
8.1

History of diabetes, %

71.9(6.2)

Family history of cancer, %

Age, y*

None

Characteristics of participants according to antibiotic use at age 20–39, NHS 2004

Author Manuscript
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1(referent)
1(referent)

Age-adjusted* OR (95% CI)

Multivariable† OR (95% CI)

No. of cases (n=163)

13

1(referent)

Multivariable† OR (95% CI)

Rectal

1(referent)

Age-adjusted* OR (95% CI)

No. of cases (n=509)

67

1(referent)

Multivariable† OR (95% CI)

Distal

1(referent)

Age-adjusted* OR (95% CI)

No. of cases (n=709)

82

1(referent)

Multivariable† OR (95% CI)

Proximal

1(referent)

Age-adjusted* OR (95% CI)

No. of cases (n=630)

73

1(referent)

Multivariable† OR (95% CI)

Low risk

1(referent)

51

Age-adjusted* OR (95% CI)

No. of cases (n=436)

High risk‡

1(referent)

Multivariable† OR (95% CI)

141
1(referent)

Age-adjusted* OR (95% CI)

No. of cases (n=1195)

Total adenoma

None

1.84(1.00–3.38)

1.88(1.03–3.43)

96

0.98(0.74–1.30)

0.99(0.75–1.30)

271

1.17(0.91–1.51)

1.18(0.92–1.51)

391

1.08(0.82–1.41)

1.08(0.83–1.40)

331

1.23(0.90–1.68)

1.25(0.92–1.71)

251

1.12(0.92–1.36)

1.13(0.93–1.37)

653

1–14 d

2.23(1.16–4.30)

2.21(1.15–4.24)

40

1.31(0.96–1.81)

1.29(0.94–1.76)

128

1.46(1.10–1.93)

1.46(1.11–1.92)

176

1.47(1.09–1.97)

1.47(1.10–1.96)

167

1.43(1.00–2.05)

1.40(0.99–2.00)

100

1.41(1.13–1.75)

1.40(1.13–1.74)

296

15 d–2 mo

Antibiotic use at age 20–39

1.95(0.87–4.37)

2.16(0.99–4.71)

14

1.18(0.78–1.78)

1.20(0.81–1.79)

43

1.43(1.00–2.04)

1.36(0.96–1.93)

60

1.42(0.98–2.05)

1.40(0.97–2.00)

59

1.37(0.86–2.16)

1.35(0.86–2.11)

34

1.36(1.03–1.79)

1.36(1.04–1.79)

105

2 mo+

0.17

0.12

0.04

0.04

0.01

0.02

0.002

0.002

0.14

0.22

0.002

0.001

Ptrend
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Antibiotic use at age 20–39 and risk of colorectal adenoma, NHS 2004–2010
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High-risk adenomas include adenoma ≥1cm, or with tubulovillous/villous histology, or ≥3 adenomas.

‡

Additionally adjusted for family history of colorectal cancer, history of diabetes, menopausal status and postmenopausal hormone use, body mass index, height, regular use of aspirin, current use of
multivitamin, alcohol intake, smoking, total calorie, folate, calcium intake, red and processed meat intake, and Alternate Healthy Eating Index (AHEI) 2010.

Adjusted for age, time period of colonoscopy, number of reported endoscopies, time since most recent endoscopy and reason for current colonoscopy.
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1(referent)
1(referent)

Age-adjusted* OR (95% CI)

Multivariable† OR (95% CI)

No. of cases (n=163)

11

1(referent)

Multivariable† OR (95% CI)

Rectal

1(referent)

Age-adjusted* OR (95% CI)

No. of cases (n=509)

34

1(referent)

Multivariable† OR (95% CI)

Distal

1(referent)

Age-adjusted* OR (95% CI)

No. of cases (n=709)

29

1(referent)

Multivariable† OR (95% CI)

Proximal

1(referent)

Age-adjusted* OR (95% CI)

No. of cases (n=630)

32

1(referent)

Multivariable† OR (95% CI)

Low risk

1(referent)

26

Age-adjusted* OR (95% CI)

No. of cases (n=436)

High risk‡

1(referent)

Multivariable† OR (95% CI)

66
1(referent)

Age-adjusted* OR (95% CI)

No. of cases (n=1195)

Total adenoma

None

1.16(0.61–2.21)

1.20(0.64–2.28)

92

1.04(0.72–1.50)

1.11(0.78–1.60)

269

1.89(1.28–2.79)

1.84(1.25–2.71)

382

1.37(0.95–1.99)

1.41(0.98–2.05)

332

1.32(0.87–2.02)

1.34(0.89–2.02)

241

1.32(1.01–1.72)

1.35(1.04–1.75)

637

1–14 d

1.14(0.57–2.29)

1.20(0.61–2.36)

44

1.15(0.78–1.68)

1.20(0.82–1.76)

142

2.29(1.53–3.42)

2.24(1.51–3.34)

228

1.61(1.10–2.37)

1.66(1.13–2.43)

194

1.43(0.92–2.22)

1.42(0.92–2.19)

123

1.51(1.14–1.99)

1.53(1.17–2.01)

357

15 d-2 mo

Antibiotic use at age 40–59

1.37(0.62–3.04)

1.34(0.61–2.95)

16

1.49(0.96–2.29)

1.67(1.09–2.55)

64

2.13(1.35–3.35)

2.07(1.32–3.22)

70

1.74(1.13–2.70)

1.82(1.19–2.80)

72

1.60(0.97–2.65)

1.64(1.00–2.67)

46

1.69(1.24–2.31)

1.74(1.28–2.37)

135

2 mo+

0.56

0.64

0.02

0.01

0.01

0.01

0.01

0.01

0.12

0.11

0.001

<0.001

Ptrend

Author Manuscript

Antibiotic use at age 40–59 and risk of colorectal adenoma, NHS 2004–2010

Author Manuscript
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High-risk adenomas include adenoma ≥1cm, or with tubulovillous/villous histology, or ≥3 adenomas.

‡

Additionally adjusted for family history of colorectal cancer, history of diabetes, menopausal status and postmenopausal hormone use, body mass index, height, regular use of aspirin, current use of
multivitamin, alcohol intake, smoking, total calorie, folate, calcium intake, red and processed meat intake, and Alternate Healthy Eating Index (AHEI) 2010.

Adjusted for age, time period of colonoscopy, number of reported endoscopies, time since most recent endoscopy and reason for current colonoscopy.
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1(referent)
1(referent)

Age-adjusted* OR (95% CI)

Multivariable† OR (95% CI)

No. of cases (n=25)

5

1(referent)

Multivariable† OR (95% CI)

Rectal

1(referent)

Age-adjusted* OR (95% CI)

No. of cases (n=77)

25

1(referent)

Multivariable† OR (95% CI)

Distal

1(referent)

Age-adjusted* OR (95% CI)

No. of cases (n=107)

21

1(referent)

Multivariable† OR (95% CI)

Proximal

1(referent)

Age-adjusted* OR (95% CI)

No. of cases (n=94)

26

1(referent)

Multivariable† OR (95% CI)

Low risk

1(referent)

16

Age-adjusted* OR (95% CI)

No. of cases (n=67)

High risk‡

1(referent)

Multivariable† OR (95% CI)

45
1(referent)

Age-adjusted* OR (95% CI)

No. of cases (n=180)

Total adenoma

None

1.43(0.50–4.10)

1.32(0.46–3.82)

12

0.60(0.34–1.06)

0.60(0.35–1.04)

27

1.11(0.64–1.92)

1.12(0.66–1.91)

42

0.63(0.36–1.11)

0.62(0.36–1.06)

29

0.96(0.52–1.80)

1.00(0.54–1.86)

29

0.84(0.56–1.26)

0.84(0.57–1.23)

68

1–14 d

0.86(0.25–2.91)

0.81(0.23–2.85)

5

0.69(0.37–1.31)

0.69(0.38–1.26)

20

1.64(0.93–2.87)

1.53(0.89–2.63)

36

1.14(0.64–2.01)

1.04(0.61–1.78)

31

0.72(0.36–1.47)

0.74(0.36–1.52)

14

1.02(0.66–1.56)

0.98(0.65–1.47)

51

15 d-2 mo

Antibiotic use in the past 4 years

1.77(0.43–7.39)

1.61(0.38–6.74)

3

0.63(0.22–1.77)

0.59(0.22–1.56)

5

1.25(0.54–2.89)

1.17(0.51–2.68)

8

0.99(0.42–2.31)

0.95(0.43–2.13)

8

1.59(0.66–3.81)

1.43(0.60–3.40)

8

1.10(0.60–2.02)

1.06(0.59–1.91)

16

2 mo+

0.87

0.93

0.59

0.47

0.18

0.29

0.27

0.35

0.62

0.76

0.44

0.54

Ptrend

Antibiotic use in the past 4 years and risk of colorectal adenoma, NHS 2008–2010

Author Manuscript
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High-risk adenomas include adenoma ≥1cm, or with tubulovillous/villous histology, or ≥3 adenomas.

‡

Additionally adjusted for family history of colorectal cancer, history of diabetes, menopausal status and postmenopausal hormone use, body mass index, height, regular use of aspirin, current use of
multivitamin, alcohol intake, smoking, total calorie, folate, calcium intake, red and processed meat intake, and Alternate Healthy Eating Index (AHEI) 2010.

Adjusted for age, time period of colonoscopy, number of reported endoscopies, time since most recent endoscopy and reason for current colonoscopy.
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Supplemental Table 1. Antibiotic use at age 20-39 and risk of colorectal adenoma by size, histology and multiplicity, NHS 2004-2010
None
Large
No. of cases (n=305)
Age-adjusted* OR (95% CI)
Multivariable† OR (95% CI)
Small
No. of cases (n=884)
Age-adjusted* OR (95% CI)
Multivariable† OR (95% CI)
Villous
No. of cases (n=177)
Age-adjusted* OR (95% CI)
Multivariable† OR (95% CI)
Tubular
No. of cases (n=836)
Age-adjusted* OR (95% CI)
Multivariable† OR (95% CI)
≥3 Adenomas
No. of cases (n=144)
Age-adjusted* OR (95% CI)
Multivariable† OR (95% CI)
1-2 Adenoma(s)
No. of cases (n=1051)
Age-adjusted* OR (95% CI)
Multivariable† OR (95% CI)

Antibiotic use at age 20-39
1-14 d
15 d-2 mo

2 mo+

Ptrend

32
1(referent)
1(referent)

176
1.34(0.91-1.97)
1.32(0.89-1.95)

72
1.52(0.98-2.33)
1.57(1.02-2.43)

25
1.46(0.85-2.51)
1.56(0.90-2.71)

0.22
0.10

104
1(referent)
1(referent)

477
1.12(0.90-1.40)
1.12(0.89-1.40)

223
1.43(1.12-1.83)
1.43(1.11-1.83)

80
1.40(1.03-1.91)
1.37(1.00-1.88)

0.001
0.003

22
1(referent)
1(referent)

105
1.27(0.78-2.05)
1.23(0.76-1.99)

34
1.17(0.66-2.09)
1.15(0.65-2.03)

16
1.57(0.80-3.10)
1.51(0.75-3.05)

0.43
0.48

101
1(referent)
1(referent)

440
1.05(0.84-1.32)
1.05(0.83-1.32)

222
1.45(1.13-1.86)
1.44(1.12-1.86)

73
1.30(0.95-1.78)
1.31(0.95-1.80)

0.001
0.002

15
1(referent)
1(referent)

85
1.51(0.87-2.63)
1.57(0.88-2.80)

33
1.69(0.90-3.18)
1.82(0.95-3.49)

11
1.64(0.75-3.61)
1.82(0.81-4.11)

0.33
0.22

126
1(referent)
1(referent)

568
1.08(0.88-1.33)
1.07(0.87-1.32)

263
1.37(1.09-1.72)
1.37(1.09-1.72)

94
1.33(1.00-1.77)
1.31(0.98-1.75)

0.002
0.003

*Adjusted for age, time period of colonoscopy, number of reported endoscopies, time since most recent endoscopy and reason for current
colonoscopy.
†Additionally adjusted for family history of colorectal cancer, history of diabetes, menopausal status and postmenopausal hormone use, body mass
index, height, regular use of aspirin, current use of multivitamin, alcohol intake, smoking, total calorie, folate, calcium intake, red and processed
meat intake, and Alternate Healthy Eating Index (AHEI) 2010.
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Supplemental Table 2. Antibiotic use at age 40-59 and risk of colorectal adenoma by size, histology and multiplicity, NHS 2004-2010
None
Large
No. of cases (n=305)
Age-adjusted* OR (95% CI)
Multivariable† OR (95% CI)
Small
No. of cases (n=884)
Age-adjusted* OR (95% CI)
Multivariable† OR (95% CI)
Villous
No. of cases (n=177)
Age-adjusted* OR (95% CI)
Multivariable† OR (95% CI)
Tubular
No. of cases (n=836)
Age-adjusted* OR (95% CI)
Multivariable† OR (95% CI)
≥3 Adenomas
No. of cases (n=144)
Age-adjusted* OR (95% CI)
Multivariable† OR (95% CI)
1-2 Adenoma(s)
No. of cases (n=1051)
Age-adjusted* OR (95% CI)
Multivariable† OR (95% CI)

Antibiotic use at age 40-59
1-14 d
15 d-2 mo

2 mo+

Ptrend

18
1(referent)
1(referent)

168
1.32(0.81-2.15)
1.32(0.79-2.18)

89
1.42(0.85-2.38)
1.46(0.86-2.47)

30
1.46(0.81-2.64)
1.48(0.80-2.72)

0.34
0.29

47
1(referent)
1(referent)

469
1.39(1.02-1.88)
1.35(0.99-1.83)

263
1.58(1.15-2.18)
1.53(1.11-2.10)

105
1.89(1.32-2.70)
1.81(1.26-2.60)

<0.001
0.001

12
1(referent)
1(referent)

97
1.20(0.65-2.20)
1.15(0.62-2.12)

47
1.22(0.64-2.34)
1.15(0.60-2.21)

21
1.70(0.82-3.50)
1.59(0.76-3.33)

0.17
0.24

45
1(referent)
1(referent)

442
1.36(0.99-1.86)
1.36(0.99-1.87)

257
1.60(1.15-2.21)
1.60(1.15-2.23)

92
1.71(1.18-2.47)
1.68(1.16-2.45)

0.003
0.01

7
1(referent)
1(referent)

85
1.79(0.82-3.92)
1.67(0.76-3.66)

38
1.71(0.75-3.90)
1.66(0.73-3.77)

14
1.96(0.77-4.98)
1.76(0.69-4.55)

0.57
0.64

59
1(referent)
1(referent)

552
1.29(0.98-1.71)
1.28(0.97-1.69)

319
1.51(1.13-2.01)
1.49(1.11-1.99)

121
1.71(1.24-2.37)
1.69(1.21-2.34)

<0.001
<0.001

*Adjusted for age, time period of colonoscopy, number of reported endoscopies, time since most recent endoscopy and reason for current
colonoscopy.
†Additionally adjusted for family history of colorectal cancer, history of diabetes, menopausal status and postmenopausal hormone use, body mass
index, height, regular use of aspirin, current use of multivitamin, alcohol intake, smoking, total calorie, folate, calcium intake, red and processed
meat intake, and Alternate Healthy Eating Index (AHEI) 2010.
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Supplemental Table 3. Joint analysis of antibiotic use at age 20-39 and 40-59 and risk of colorectal adenoma*, NHS 2004-2010
Age 20-39
Age 40-59
None
1-14 d
15 d+
None
34
88
20
1(referent)
1.29(0.86-1.95)
1.26(0.70-2.28)
1-14 d
28
489
151
1.06(0.63-1.78)
1.37(0.95-1.97)
1.47(1.00-2.18)
15 d+
4
72
327
1.01(0.34-2.94)
1.56(1.02-2.40)
1.73(1.19-2.51)

3
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Supplemental Table 4. Reason for antibiotic use and risk of colorectal
adenoma, NHS 2008-2010
No. of cases/non-cases
52/1724
Respiratory infection
30/629
UTI
1/55
Acne/Rosacea
2/96
Chronic Bronchitis
27/842
Dental
22/795
Other Reason
*Adjusted for the same set of covariates as in Table 2.

OR (95% CI)
1(referent)
1.50(0.94-2.39)
0.50(0.07-3.80)
0.71(0.17-3.04)
1.10(0.67-1.81)
0.87(0.51-1.48)
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